Design of an anticancer organoruthenium complex as the guest and polydiacetylene-coated fluorogenic nanocarrier as the host: engineering nanocarrier using ene-yne conjugation for sustained guest release, enhanced anticancer activity and reduced <i>in vivo</i> toxicity-Reference-Cited by-同舟云学术

Design of an anticancer organoruthenium complex as the guest and polydiacetylene-coated fluorogenic nanocarrier as the host: engineering nanocarrier using ene-yne conjugation for sustained guest release, enhanced anticancer activity and reduced in vivo toxicity

Published:2024 Issue:3 Volume:53 Page:966-985
ISSN:1477-9226
Container-title:Dalton Transactions
language:en
Short-container-title:Dalton Trans.

Author:

Sumithaa Chezhiyan¹^ORCID,Gajda-Morszewski Przemyslaw²³^ORCID,Ishaniya Wickneswaran¹^ORCID,Khamrang Themmila⁴,Velusamy Marappan⁵^ORCID,Bhuvanesh Nattamai⁶,Brindell Malgorzata²^ORCID,Mazuryk Olga²^ORCID,Ganeshpandian Mani¹^ORCID

Affiliation:

1. Department of Chemistry, SRM Institute of Science and Technology, Kattankulathur 603 203, Tamil Nadu, India

2. Faculty of Chemistry, Department of Inorganic Chemistry, Jagiellonian University, Gronostajowa 2, 30-387, Cracow, Poland

3. Doctoral School of Exact and Natural Sciences, Jagiellonian University, Łojasiewicza 11, 30-348 Cracow, Poland

4. Department of Chemistry, Dhanamanjuri University, Manipur 795001, India

5. Department of Chemistry, North Eastern Hill University, Shillong 793022, India

6. X-ray Diffraction Lab, Department of Chemistry, Texas A&M University, College Station, TX 77842, USA

Abstract

Engineering mesoporous silica nanoparticles into a fluorogenic and pH-responsive carrier for organoruthenium complex delivery into colorectal cancer cells.

Funder

Science and Engineering Research Board

Department of Science and Technology, Ministry of Science and Technology

Publisher

Royal Society of Chemistry (RSC)

Subject

Inorganic Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2024/DT/D3DT03358A

Reference67 articles.

1. Challenges and Opportunities in the Development of Organometallic Anticancer Drugs

2. The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs

3. Intrinsic and Acquired Forms of Resistance against the Anticancer Ruthenium Compound KP1019 [Indazoliumtrans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A)

4. A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent

5. Preclinical combination therapy of the investigational drug NAMI-A+ with doxorubicin for mammary cancer